3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
12
Unknown
6
Terminated
2
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
16
Triple Negative Breast Neoplasms
4
Neoplasms
2
Stomach Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Lymphoma
1
Inflammatory Breast Neoplasms
1
Hodgkin Disease
1
Down Syndrome
1
Interventions
Paclitaxel
6
Cyclophosphamide
5
pembrolizumab
3
Taxes
3
Specimen Handling
3
Doxorubicin
3
Carboplatin
3
eribulin
2
Trastuzumab
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
sargramostim
1
ruxolitinib
1
pertuzumab
1
onvansertib
1
olaparib
1
cobimetinib
1
atezolizumab
1
X-Rays
1
Therapeutics
1
Radiotherapy
1
Radiation
1
Panitumumab
1
Palliative Care
1
Methods
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
Gonadotropin-Releasing Hormone
1
Exercise Test
1
Epirubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Inflammatory Breast Neoplasms
×
Epirubicin
×
Clear all
NCT03515798
2025-09-12
PELICAN
Institut Paoli-Calmettes
Phase 2
Active not recruiting
52 enrolled